NeoGenomics Inc. Shares Surge Above 200-Day Moving Average.
ByAinvest
Monday, Oct 13, 2025 11:36 am ET1min read
NEO--
The 200-day moving average is a widely used technical indicator that helps investors gauge the trend direction of a stock. NEO's recent upward movement suggests a positive trend, as it has broken above this key level. The stock's 52-week range is between $4.72 and $19.115, with the last trade at $9.30.
One of the primary drivers behind NEO's stock performance is its recent legal victory. The District Court for the Middle District of North Carolina granted summary judgment in NeoGenomics' patent infringement lawsuit against Natera, allowing the company to freely commercialize its RaDaR ST molecular residual disease (MRD) assay in the United States . This ruling is expected to boost the company's revenue and market share in the precision diagnostics sector.
Additionally, NEO has been expanding its product offerings, including the launch of the PanTracer LBx blood-based comprehensive genomic profiling test, which analyzes over 500 genes and offers a 7-day turnaround time . This strategic move positions NEO in the $3-5 billion liquid biopsy market, complementing its existing tissue-based testing portfolio.
The company's financial results for the second quarter of 2025 also contributed to the stock's performance. Despite a net loss of $45 million, up 142% year-over-year, NEO reported a 10% increase in consolidated revenue to $181 million, driven by higher-value tests and strategic reimbursement initiatives .
However, NEO's full-year 2025 guidance was revised downward, citing pressure in pharma revenue and delays in the PanTracer™ Liquid Biopsy launch . This suggests that while the company has made significant strides in expanding its product offerings and legal position, it faces challenges in meeting its financial targets.
Overall, NEoGenomics Inc (NEO) shares have shown strong performance, driven by key developments in the company's operations and financial performance. Investors should continue to monitor the company's progress and upcoming events, such as its third quarter 2025 financial results announcement scheduled for October 28, 2025 [1].
NEO--
NeoGenomics Inc (NEO) shares have crossed above their 200-day moving average of $9.36, reaching a high of $9.62 per share. The stock is currently up 1.5% on the day. NEO's 52-week range is between $4.72 and $19.115, with a last trade of $9.30.
NeoGenomics Inc (NEO) shares have seen a notable surge, crossing above their 200-day moving average of $9.36 and reaching a high of $9.62 per share. This move represents a 1.5% increase in the stock's value on the day, driven by several key developments in the company's operations and financial performance.The 200-day moving average is a widely used technical indicator that helps investors gauge the trend direction of a stock. NEO's recent upward movement suggests a positive trend, as it has broken above this key level. The stock's 52-week range is between $4.72 and $19.115, with the last trade at $9.30.
One of the primary drivers behind NEO's stock performance is its recent legal victory. The District Court for the Middle District of North Carolina granted summary judgment in NeoGenomics' patent infringement lawsuit against Natera, allowing the company to freely commercialize its RaDaR ST molecular residual disease (MRD) assay in the United States . This ruling is expected to boost the company's revenue and market share in the precision diagnostics sector.
Additionally, NEO has been expanding its product offerings, including the launch of the PanTracer LBx blood-based comprehensive genomic profiling test, which analyzes over 500 genes and offers a 7-day turnaround time . This strategic move positions NEO in the $3-5 billion liquid biopsy market, complementing its existing tissue-based testing portfolio.
The company's financial results for the second quarter of 2025 also contributed to the stock's performance. Despite a net loss of $45 million, up 142% year-over-year, NEO reported a 10% increase in consolidated revenue to $181 million, driven by higher-value tests and strategic reimbursement initiatives .
However, NEO's full-year 2025 guidance was revised downward, citing pressure in pharma revenue and delays in the PanTracer™ Liquid Biopsy launch . This suggests that while the company has made significant strides in expanding its product offerings and legal position, it faces challenges in meeting its financial targets.
Overall, NEoGenomics Inc (NEO) shares have shown strong performance, driven by key developments in the company's operations and financial performance. Investors should continue to monitor the company's progress and upcoming events, such as its third quarter 2025 financial results announcement scheduled for October 28, 2025 [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet